Richard Scott Struthers - 16 Mar 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
16 Mar 2023
Transactions value $
-$79,231
Form type
4
Filing time
17 Mar 2023, 17:10:27 UTC
Previous filing
03 Mar 2023
Next filing
21 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Tax liability -$79,231 -4,628 -3.6% $17.12 125,522 16 Mar 2023 Direct F1
holding CRNX Common Stock 1,000 16 Mar 2023 By Spouse
holding CRNX Common Stock 730,805 16 Mar 2023 By Family Trust 1
holding CRNX Common Stock 90,000 16 Mar 2023 By Family Trust 2
holding CRNX Common Stock 90,000 16 Mar 2023 By Family Trust 3
holding CRNX Common Stock 90,000 16 Mar 2023 By Family Trust 4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.